MEDICINOVA, INC.

Analyst Reco. MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
1.33 ^USD	-2.92%		-4.32%	-11.33%

Jun. 05	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer	CI
Jun. 03	MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova Says Alcohol-Use Disorder Drug Reduced Rates of Heavy Drinking, Alcohol Craving in Mid-Stage Trial	22-04-08	MT
Maxim Group Adjusts MediciNova Price Target to $6 From $10, Maintains Buy Rating	22-02-02	MT
B. Riley Lowers MediciNova's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
MEDICINOVA : Maxim Starts MediciNova at Buy With $15 Price Target	21-03-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer